The new chemical for eyelashes has been created by Allergan, the company behind the anti-wrinkle drug Botox.
Allergan has won approval in the US to sell a prescription medication that promises to enhance dull or thinning lashes.
Latisse, which is designed to treat a condition known as hypotrichosis of the eyelashes, which means a person does not have enough eyelashes, has been approved by the Food and Drug Administration (FDA).
When applied once daily to the eyelid with a disposable applicator, the drug Latisse apparently improves the length, thickness and colour of hairs.
Continued use is necessary to maintain the thicker lashes, and side effects can include eye redness and itchiness, a darkening of the eyelid skin and a permanent darkening of the whites of the eyes.
The primary ingredient in Latisse is a chemical called a prostaglandin, which is present in hair and is thought to help in the development and regrowth of hair follicles.
The same chemical is used to treat glaucoma, and it was a glaucoma specialist who first discovered the eyelash effect.
Latisse be available early next year and and a 30-day supply is expected to cost $120 (£82), according to reports.
Latisse is the first prescription product for lengthening eyelashes and the company said it estimates that global sales could top £300million a year.
...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!... ...!...
AN/Today
Africa News Today
"One better Africa is possible"
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
No comments:
Post a Comment